Dupilumab Treatment Is Associated With Clinical Improvement and a Shift Toward a Health‐Associated Nasal Passage Microbiota in Diffuse Type 2 Chronic Rhinosinusitis
Authors:
- Fabio S. RyserFRFabio S. Ryser
- Tomas DemeterTDTomas Demeter
- Judith Bergada PijuanJPJudith Bergada Pijuan
- Srikanth Mairpady ShambatSSSrikanth Mairpady Shambat
- Tina MautheTMTina Mauthe
- Markus HiltyMHMarkus Hilty
- Michael B. SoykaMSMichael B. Soyka
- Urs C. SteinerUSUrs C. Steiner
- Silvio D. BruggerSBSilvio D. Brugger
Top Cited Papers
Open Access
Abstract
Background: Nasal microbiota composition of patients with diffuse type 2 chronic rhinosinusitis with nasal polyps (CRSwNP) is altered compared to healthy individuals. Dupilumab, an anti‐IL‐4Rα‐mAb, modulates type 2 inflammation, but the effect on microbiota composition in CRSwNP is unknown. The aim of this study was to investigate longitudinal effects of dupilumab on the nasal passage and gastrointestinal microbiota in patients with diffuse type 2 CRSwNP.Methods: Twenty‐seven patients with diffuse type 2 CRSwNP treated with dupilumab 300 mg subcutaneously every 2 weeks, 10 untreated patients with CRSwNP, and 11 healthy controls were included. Nasal and stool samples were collected at Days 0, 28, 90, and 180 posttreatment of the treated CRSwNP group and at Days 0 and 28 of untreated CRSwNP and healthy controls. The samples were analyzed using 16S rRNA gene amplicon sequencing (V3/V4).Results: In CRSwNP patients, the most abundant genera in nasal passage microbiota were Corynebacterium and Staphylococcus. Cutibacterium and Lawsonella were less abundant in CRSwNP at baseline compared to healthy controls. Dupilumab treatment was associated with increased relative abundances in the nasal passage of genera such as Lawsonella, Corynebacterium, and Dolosigranulum. Microbial diversity of the gastrointestinal microbiota in CRSwNP at baseline was significantly higher than in healthy controls. There were no changes in gastrointestinal microbiota during dupilumab treatment.Conclusion: Dupilumab treatment was associated with a shift in the nasal passage bacterial microbiota toward that of healthy controls, whereas the composition of gastrointestinal microbiota did not change. These findings suggest that nasal passage microbiota composition is influenced by the underlying inflammatory endotype.Keywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (211422)
This publication has 61 references indexed in Scilit:
- Butyrate inhibits type 2 inflammation in eosinophilic chronic rhinosinusitisBiochemical and Biophysical Research Communications, 2024
- Microbiota-derived butyrate restricts tuft cell differentiation via histone deacetylase 3 to modulate intestinal type 2 immunityImmunity, 2024
- Tuft cells in the pathogenesis of chronic rhinosinusitis with nasal polyps and asthmaAnnals of Allergy, Asthma & Immunology, 2020
- Contemporary Classification of Chronic Rhinosinusitis Beyond Polyps vs No PolypsJAMA Otolaryngology–Head & Neck Surgery, 2020
- Distinct Clinical Pathology and Microbiota in Chronic Rhinosinusitis With Nasal Polyps EndotypesThe Laryngoscope, 2020
- Association of chronic rhinosinusitis with high microbiome dissimilarity among different patients and within individuals over timeAnnals of Allergy, Asthma & Immunology, 2020
- Lactobacilli Have a Niche in the Human NoseCell Reports, 2020
- The Association Between Disease Severity and Microbiome in Chronic RhinosinusitisThe Laryngoscope, 2019
- Clinical efficacy of a topical lactic acid bacterial microbiome in chronic rhinosinusitis: A randomized controlled trialLaryngoscope Investigative Otolaryngology, 2017
- Specific IgE against Staphylococcus aureus enterotoxins: An independent risk factor for asthmaJournal of Allergy and Clinical Immunology, 2012